Cytochrome P450 isoenzymes - Importance for the internist

Netherlands Journal of Medicine

Volumn 48, Issue 6, 1996, Pages 237-238

  Kerremans, A L M ^a  

^a ELKERLIEK HOSPITAL   (Netherlands)

Author keywords

Cytochrome P450 isoenzymes; Drug interactions; Drug metabolism

Indexed keywords

AJMALINE; AMITRIPTYLINE; CAFFEINE; CIMETIDINE; CITALOPRAM; CLOMIPRAMINE; COUMARIN; CYTOCHROME P450; DIAZEPAM; FELBAMATE; FLUVOXAMINE; FURAFYLLINE; IMIPRAMINE; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PHENACETIN; PHENAZONE; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL; QUINIDINE; RIFAMPICIN; SPARTEINE; SULFAPHENAZOLE; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG; XENOBIOTIC AGENT;

ARTICLE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; DRUG TOXICITY; GENETIC POLYMORPHISM; HUMAN; LIVER METABOLISM; PHENOTYPE;

EID: 0029922646     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-2977(96)00002-2     Document Type: Review

References (36)

1. Batt AM, Magdalou J, Vincent-Viry M, et al. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP glucuronosyltransferases. Clin Chim Acta 1994;226:171-190.
2. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-239.
3. Halpert JR, Guengerich FP, Bend JR, Correia MA. Contemporary issues in toxicology: selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 1994;125:163-175.
4. La Bella FS. Cytochrome P450 enzymes: ubiquitous 'receptors' for drugs. Can J Physiol Pharmacol 1991;69:1129-1132.
5. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992;44:2089-2098.
6. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
7. Nelson DR, Kamataki T, Waxman DJ et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers;early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
8. Masimirembwa CM, Beke M, Hasler JA et al. Low CYP 1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther 1995;57:25-31.
9. Lebrethon MC, Jaillard C, Defayes G et al. Human cultured adrenal fasciculata-reticularis cells are targets for angiotensin II: effects on cytochrome P450 cholesterol side-chain cleavage, cytochrome P450 17 alpha-hydroxylase, and 3 beta hydroxysteroid dehydrogenase messenger ribonucleic acid and proteins and on steroidogenic responsiveness to corticotropin and angiotensin II. J Clin Endocrinol Metab 1994;78:1212-1219.
10. Agundez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP 2-D-6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57:265-269.
11. Al-Hadidi HF, Irshaid YM, Rawashdeh NM. Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP 2-D-6) polymorphism in Jordanians. Eur J Clin Pharmacol 1994;47:311-314.
12. Brosen K, Nielsen PN, Brusgaard K et al. CYP 2-D-6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994;47:221-225.
13. Loeper J, Descatoire V, Maurice M. et al. Cytochromes P450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 1993;104:203-216.
14. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive β-blockade following timolol eye drops. J Am Med Assoc 1995;274:1611-1613.
15. Lown KS, Thummel KE, Benedict PE et al. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol Ther 1995;57:16-24.
16. Spinler SA, Cheng JWM, Kindwall KE, Charland SL. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995;57:89-94.
17. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212.
18. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995;333:1118-1127.
19. Gomez DY, Wacher VJ, Tomlanovich SJ et al. The effects of ketoconazole on the intestinal bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-19.
20. Kupferschmidt HHT, Ha HR, Ziegler WH et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-28.
21. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability and effect of naringin. Clin Pharmacol Ther 1993;53:637-642.
22. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-269.
23. Fuhr U., Kummert AL. The fate of naringin in humans: A key to grapefruit juice-drug interactions? Clin Pharmacol Ther 1995;58:365-373.
24. Lefebvre RA, Flouvat B, Karolac-Tamisier S et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992;52:458-463.
25. Glauser TA, Kerremans ALM, Weinshilboum RM. Human hepatic microsomal thiolmethyltransferase: assay conditions, biochemical properties and correlation studies. Drug Metab Disposit 1992;20:247-255.
26. Birkett DJ, Mackenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci (TIPS) 1993;14:292-294.
27. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2-E-1. Clin Pharmacol Ther 1993;53:643-650.
28. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP 2E1 activity. Clin Pharmacol Ther 1994;56:359-367.
29. Yu MW, Gladek-Yarborough A, Chiamprasert S et al. Cytochrome P450-2E1 and glutathione S transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995;109:1266-1273.
30. Catteau A, Bechtel YC, Poisson N et al. A population and family study of CYP 1-A-2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995;47:423-430.
31. Agundez JAG, Jimenez-Jimenez FJ, Luengo A et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995;57:291-298.
32. Masimirembwa CM, Hasler JA, Johansson I. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol 1995;48:35-38.
33. Transon C. Leemann Th, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450 TB (CYP 2C9) by fluvastatin. Clin Pharmacol Ther 1995;58:412-417.
34. Hulsman JARJ, Rentmeester ThW, Banfield CR et al. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Clin Pharmacol Ther 1995;58:383-389.
35. Fromm MF, Hofmann U, Griese EU, Mikus G. Dihydrocodeine: a new opioid substrate for the polymorphic CYP 2D6 in humans. Clin Pharmacol Ther 1995;58:374-382.
36. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399-403.